Innovent Biologics

"Start with Integrity, Succeed through Action" - developing high-quality biologics that patients can afford is the mission and goal of Innovent Biologics. Founded in 2011, Innovent Biologics is committed to the research, development, manufacturing, and commercialization of innovative drugs for major disease areas such as oncology, autoimmune diseases, metabolic diseases, and ophthalmology, so that our work can benefit more lives. The company has 18 products approved for marketing, which are Sintilimab Injection (Tyvyt®), Bevacizumab Injection (Byvasda®), Adalimumab Injection (Sulinno®), Rituximab Injection (Dabohua®), Pemigatinib Tablets (Pemazyre®), Olverembatinib Tablets (Nailike®), Ramucirumab Injection (Cyramza®), Selpercatinib Capsules (Retevmo®), Equecabtagene Autoleucel Injection (Fucaso®), Tafolecimab Injection (Sintbilo®), Fuzetazide Tablets (Dabote®), Pirtobrutinib Tablets (Jaypirca®), Taletrectinib Adipate Capsules (Dabole®), Lierutinib Tablets (Aoyixin®), Telitacicept N01 Injection (Xinbimin®), Mazdutide Injection (Xin'ermei®), Pikangkimab Injection (Xinmeiyue®), and Ipilimumab N01 Injection (Daboxin®). Currently, 4 new drug molecules are in Phase III or pivotal clinical studies, and another 15 new drug candidates have entered clinical research.

The company has established more than 30 strategic collaborations with international partners such as Eli Lilly, Roche, Takeda, Sanofi, Incyte, and MD Anderson Cancer Center. While continuously developing innovative drugs and pursuing its own growth, Innovent Biologics adheres to a people-centered development philosophy in economic construction. Over the years, it has always upheld scientific goodwill, adhered to a "patient-centric" approach, cared for patients and their families, and actively fulfilled its social responsibilities. The company has initiated and participated in multiple drug assistance programs, enabling more and more patients to benefit from advances in life sciences, and to have access to and afford high-quality biologics. To date, Innovent Biologics' patient assistance programs have benefited over 200,000 ordinary patients, with a total value of drug donations amounting to RMB 3.6 billion. Innovent Biologics hopes to work together with everyone to improve the development level of China's biopharmaceutical industry, so as to meet the public's need for drug accessibility and their aspirations for health and well-being.